STOCK TITAN

BioLineRx agrees to $5.6M APHEXDA royalty sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

BioLineRx Ltd. agreed to sell 80% of future APHEXDA royalty payments attributable to sales on or after closing to SCOF Motixafortide Holdings, Inc., an affiliate of Soleus Capital Management, for a $5.6 million one-time purchase price at closing, less the purchaser’s documented reasonable transaction expenses capped at $100,000. The sold portion corresponds to a 14.4% royalty on net sales. BioLineRx will retain the remaining 20%, corresponding to a 3.6% royalty, as well as royalties for pre-closing periods and potential future commercial milestone payments. Closing is expected on or about November 30, 2026, subject to customary conditions and Ayrmid’s consent.

At closing, BioLineRx will make a $3.0 million partial loan prepayment to Kreos Capital VII Aggregator SCSp. Approximately $2.0 million will then remain outstanding under a new repayment schedule, and the $4.0 million minimum cash balance covenant will be eliminated. Chardan Capital Markets is due an approximately $0.4 million advisory fee at closing. If completed, BioLineRx intends to use net proceeds for research and development, including GLIX1, working capital and general corporate purposes. GLIX1’s Phase 1/2a trial is enrolling its fourth of five planned dosing cohorts.

Purchase price $5.6 million One-time payment at closing for the Purchased Receivables, less documented reasonable purchaser expenses capped at $100,000.
Royalty payments sold 80% Payments attributable to APHEXDA sales on or after closing.
Royalty interest sold 14.4% Royalty on APHEXDA net sales corresponding to the portion sold.
Royalty interest retained 3.6% Royalty on APHEXDA net sales corresponding to the retained 20% of payments.
Loan prepayment $3.0 million Partial prepayment to Kreos at closing.
Remaining loan amount Approximately $2.0 million Outstanding after the partial prepayment; to be repaid under a new schedule.
Minimum cash balance covenant $4.0 million Covenant under the Loan Agreement to be eliminated at closing.
Financial advisory fee Approximately $0.4 million Fee payable to Chardan Capital Markets upon closing.
Purchased Receivables financial
"the “Purchased Receivables”"
minimum cash balance covenant financial
"the minimum cash balance covenant under the Loan Agreement"
floating charge financial
"an amendment to the Company’s floating charge in favor of Kreos"
CXCR4 antagonist medical
"APHEXDA is a CXCR4 antagonist"
A CXCR4 antagonist is a medicine that blocks a specific cell surface receptor called CXCR4, stopping signals that guide cell movement and survival. Think of it like putting a padlock on a door that cancer cells or immune cells use to travel and hide; this can slow tumor spread, help release stem cells for transplant, or interfere with viruses. For investors, drugs using this mechanism can create clear clinical milestones, niche market opportunities, and regulatory risks tied to trial results.
autologous stem cell transplantation medical
"subsequent autologous stem cell transplantation in patients with multiple myeloma"
A procedure that collects a patient’s own stem cells, stores them, and then returns them after intensive treatment that wipes out diseased or malfunctioning cells. Think of it like saving seeds before clearing a garden and replanting them afterward to restore growth. Investors watch this because demand, costs, and outcomes influence sales of related drugs, devices and services, reimbursement decisions, and the commercial potential of new therapies.
Phase 1/2a clinical trial medical
"a Phase 1/2a clinical trial has been initiated"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much will BioLineRx (BLRX) receive for its APHEXDA royalties?

BioLineRx is to receive a one-time $5.6 million purchase price at closing, less the purchaser’s documented reasonable transaction expenses capped at $100,000. Closing is expected on or about November 30, 2026, subject to customary closing conditions.

What APHEXDA royalties will BioLineRx (BLRX) sell and retain?

It will sell 80% of royalty payments on APHEXDA sales on or after closing, corresponding to a 14.4% royalty on net sales, and retain the remaining 20%, corresponding to 3.6%. The retained portion is attributable to royalties BioLineRx is obligated to pay to Biokine Therapeutics.

How will the BioLineRx (BLRX) royalty transaction affect its loan?

At closing, BioLineRx will make a $3.0 million partial loan prepayment to Kreos Capital VII Aggregator SCSp. Approximately $2.0 million will remain outstanding under a new repayment schedule, and the $4.0 million minimum cash balance covenant will be eliminated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission file number: 001-35223

 

BioLineRx Ltd.

(Translation of registrant’s name into English)

 

2 HaMa’ayan Street

Modi’in 7177871, Israel

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒ Form 40-F ☐

 

 

On November 17, 2026, BioLineRx Ltd. (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with SCOF Motixafortide Holdings, Inc., a Delaware corporation and an affiliate of Soleus Capital Management, L.P. (the “Purchaser”), pursuant to which the Company agreed to sell to the Purchaser a portion of its right to receive future royalty payments on net sales of APHEXDA® (motixafortide) under the Company’s License Agreement with Ayrmid Pharma Ltd. (“Ayrmid”), dated November 20, 2024, as amended (the “Ayrmid License”). The transaction is expected to close on or about November 30, 2026, subject to the satisfaction of customary closing conditions.

 

Pursuant to the Purchase Agreement, the Company will sell to the Purchaser, at closing, 80% of the royalty payments payable to the Company under the Ayrmid License attributable to sales occurring on or after the closing date, together with related rights, including amounts payable in respect of any underpayment or late payment of such royalties, amounts payable in lieu thereof, and royalties payable under any replacement license entered into following a termination of the Ayrmid License (collectively, the “Purchased Receivables”). As a condition to closing, Ayrmid will consent to the sale and agree to remit the Purchased Receivables directly to the Purchaser. The Company will retain the remaining 20% of such royalty payments. Based on the 18% royalty rate payable to the Company under the Ayrmid License, the 80% interest to be sold to the Purchaser corresponds to a 14.4% royalty on net sales of APHEXDA, and the 20% interest to be retained by the Company corresponds to a 3.6% royalty on net sales, which retained portion is attributable to the royalties the Company is obligated to pay to Biokine Therapeutics Ltd., the original licensor of motixafortide to the Company, under the Company’s upstream license agreement with Biokine.

 

In consideration for the Purchased Receivables, the Purchaser will pay the Company a one-time purchase price of $5.6 million at closing, less the Purchaser’s documented reasonable transaction expenses capped at $100,000. The Company will retain, among other things, all rights to receive potential future milestone payments under the Ayrmid License.

 

In addition, Kreos Capital VII Aggregator SCSp (“Kreos”), an affiliate of BlackRock and the lender under the Company’s loan agreement dated September 14, 2022, as amended (the “Loan Agreement”), has consented to the transaction and agreed to release its security interest in the Purchased Receivables. In connection with such consent, the Company and Kreos will enter into a Second Amendment to the Loan Agreement at the closing of the Purchase Agreement (the “Loan Amendment”), pursuant to which the Company will make a partial loan prepayment to Kreos of $3.0 million at such closing. Following such prepayment, the remaining outstanding amount under the Loan Agreement of approximately $2.0 million will be repaid in accordance with a new repayment schedule, the minimum cash balance covenant under the Loan Agreement of $4.0 million will be eliminated, and an amendment to the Company’s floating charge in favor of Kreos will become effective.

 

The Purchase Agreement contains customary representations, warranties and covenants of the parties for a transaction of this nature, as well as customary closing conditions.

 

Chardan Capital Markets, LLC acted as financial advisor to the Company in connection with the transaction described herein and will receive a financial advisory fee of approximately $0.4 million, payable upon the closing of the transaction.

 

The Company intends to use the net proceeds of the transaction, if consummated, to support its ongoing research and development activities, including the clinical development of GLIX1, as well as for working capital and general corporate purposes, including the partial repayment of the Loan Agreement described above.

 

The foregoing description of the Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of such document, a copy of which is filed as Exhibit 10.1 to this Report on Form 6-K and is incorporated by reference herein.

 

On November 18, 2026, the Company issued a press release entitled “BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital.” A copy of the press release is attached hereto as Exhibit 99.1.

 

This Report on Form 6-K, including all exhibits hereto (other than the press release attached as Exhibit 99.1), is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

 

 

Attached hereto and incorporated by reference herein are the following exhibits:

 

Exhibit No.   Description
     
10.1(1)   Purchase and Sale Agreement, dated as of November 17, 2026, between BioLineRx Ltd. and SCOF Motixafortide Holdings, Inc.
     
99.1   Press Release dated November 18, 2026

 

(1) Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Registrant undertakes to furnish a copy of all omitted schedules and exhibits to the SEC upon its request.

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BioLineRx Ltd.  
       
  By: /s/ Philip A. Serlin  
    Philip A. Serlin  
    Chief Executive Officer  

 

Dated: November 18, 2026

 

 

 

Exhibit 99.1

 

 

 

For Immediate Release

 

BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

 

- Transaction provides non-dilutive capital through sale of BioLineRx's portion

of future APHEXDA royalties -

 

- Funds to support clinical development of GLIX1, including ongoing Phase 1/2a clinical trial, which is

currently enrolling the fourth of five planned dosing cohorts -

 

- BioLineRx retains rights to future commercial milestone payments under its existing

license agreement with Ayrmid -

 

TEL AVIV, Israel, November 18, 2026 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into an agreement for the sale of its rights to certain future royalty payments from APHEXDA® (motixafortide) to Soleus Capital Management, L.P. and its affiliates (“Soleus”) for a one-time payment of $5.6 million.

 

Under the terms of the agreement, Soleus will acquire BioLineRx's 14.4% royalty interest in future net sales of APHEXDA under the Company's existing license agreement with Ayrmid Pharma Ltd. (“Ayrmid”). The transaction excludes the remaining 3.6% royalty interest attributable to the original licensor of motixafortide to BioLineRx, which will continue to retain its interest in the royalty stream. BioLineRx has retained its rights to receive potential commercial milestone payments under the Ayrmid agreement, as well as royalty payments attributable to periods prior to the closing of the transaction.

 

“This transaction enables us to immediately unlock the value of our APHEXDA royalty stream and strengthen our financial position while retaining the potential for future commercial milestone payments,” said Philip Serlin, Chief Executive Officer of BioLineRx. “Importantly, the non-dilutive capital will provide additional financial flexibility as we continue to advance our lead development asset, GLIX1, through its ongoing Phase 1/2a clinical trial in glioblastoma and other solid tumors. We believe this transaction represents an attractive, non-dilutive financing solution for our company and our shareholders.”

 

“We are pleased to partner with BioLineRx on this transaction, which provides us with an opportunity to participate in the future commercial performance of APHEXDA,” said Benjamin Lund, Partner at Soleus Capital. “We believe APHEXDA represents a differentiated treatment option in stem cell mobilization for patients with multiple myeloma, and we look forward to supporting BioLineRx through this innovative financing arrangement.”

 

BioLineRx intends to use the proceeds to support its ongoing research and development activities, including the clinical development of GLIX1, as well as for working capital and general corporate purposes, including a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with the partial loan repayment, the Company’s minimum cash balance requirement under the loan agreement (currently $4 million) will be eliminated. The transaction is expected to close on or about November 30, 2026.

 

About APHEXDA® (motixafortide)

 

APHEXDA is a CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous stem cell transplantation in patients with multiple myeloma. APHEXDA is being commercialized by Ayrmid globally, except in Asia, where it is partnered with Gloria Biosciences.

 

About BioLineRx

 

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company’s lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

 

The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

 

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.

 

About Soleus Capital

 

Soleus Capital is an investment firm based in Greenwich, CT focused on the innovative areas of life sciences, including biopharmaceuticals, medical technologies, life sciences tools and diagnostics. With approximately $3.5 billion in total assets under management as of June 30, 2026, Soleus Capital invests across the healthcare lifecycle from developmental-stage through commercial, and partners with life science companies across the capital structure with hedge fund, private equity and structured credit vehicles.

 

Forward Looking Statement

 

Various statements in this release concerning BioLineRx's future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” and “would,” and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the consummation and expected benefits of the royalty monetization transaction with Soleus Capital; BioLine’s receipt and intended use of the transaction proceeds; the completion and expected effects of the partial repayment of BioLine’s outstanding loan facility, including the elimination of the minimum cash balance requirement; the future commercial performance, market uptake and net sales of APHEXDA; potential future royalty and commercial milestone payments relating to APHEXDA; the ongoing Phase 1/2a clinical trial of GLIX1, including its enrollment, progress and the timing and results of any clinical readout; and BioLineRx’s business strategy, financial position and financing requirements.. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of GLIX1 and motixafortide including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx’s preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx’s ability to advance GLIX1 and motixafortide into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for GLIX1 and motixafortide will be predictive of real-world results; BioLineRx’s receipt of regulatory approvals for GLIX1 and motixafortide and the timing of other regulatory filings and approvals; whether access to GLIX1 and motixafortide is achieved in a commercially viable manner and whether GLIX1 and motixafortide receives adequate reimbursement from third-party payors; BioLineRx’s ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx’s collaborators to execute on their development and commercialization plans; BioLineRx’s ability to integrate new therapeutic candidates and new personnel, as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx’s therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx’s business model and strategic plans for its business and therapeutic candidates; the scope of protection that BioLineRx’s is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx’s expenses, future revenues, capital requirements and its need for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx’s industry; BioLineRx’s ability to maintain the listing of its ADSs on Nasdaq; statements as to the impact of the political and security situation in Israel on BioLineRx’s business which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the “Risk Factors” section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2026. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

 

Contacts:

 

United States

Chuck Padala

LifeSci Advisors, LLC

IR@biolinerx.com

 

Israel

Moran Meir

LifeSci Advisors, LLC

moran@lifesciadvisors.com

 

 

Filing Exhibits & Attachments

2 documents

Keep reading